Company news

Adaptive Biotechnologies Corporation news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

Adaptive Biotechnologies Reports Second Quarter 2022 Financial Results

August 2, 2022

Adaptive Biotechnologies Receives Expanded Medicare Coverage of clonoSEQ® for Monitoring Minimal Residual Disease in Diffuse Large B-Cell Lymphoma

July 27, 2022

Adaptive Biotechnologies to Report Second Quarter of 2022 Financial Results on August 3, 2022

July 7, 2022

Adaptive Biotechnologies Launches T-Detect™ Lyme, A New T-Cell Clinical Test for the Detection of Early Lyme Disease

June 14, 2022

Adaptive Biotechnologies Included in Key Abstracts at ASCO 2022 Supporting the Role of the clonoSEQ® Assay as a Standard for MRD Assessment Technology

June 1, 2022

Adaptive Biotechnologies Reports First Quarter 2022 Financial Results

May 3, 2022

Adaptive Biotechnologies to Present at the BofA Securities 2022 Healthcare Conference

May 1, 2022

Adaptive Biotechnologies to Report First Quarter Financial Results on May 4, 2022

April 4, 2022

Adaptive Biotechnologies Appoints Tycho Peterson as Chief Financial Officer, Reorganizes and Streamlines Workforce to Drive Growth in Two Key Business Areas

March 8, 2022

Adaptive Biotechnologies to Present at the 42nd Annual Cowen Healthcare Conference

March 1, 2022

Adaptive Biotechnologies Announces New Data Demonstrating ImmunoSEQ® Technology Can Identify T-Cell Receptors Associated with Crohn’s Disease

February 17, 2022

Adaptive Biotechnologies Reports Fourth Quarter and Full Year 2021 Financial Results

February 14, 2022

Adaptive Biotechnologies to Present at the BTIG MedTech, Digital Health, Life Science & Diagnostic Tools Conference

February 1, 2022

Adaptive Biotechnologies to Report Fourth Quarter and Full Year 2021 Financial Results on February 15, 2022

January 23, 2022

Adaptive Biotechnologies Announces Preliminary, Unaudited 2021 Revenue Results and CFO Transition

January 9, 2022

Adaptive Biotechnologies to Present Virtually at the 40th Annual J.P. Morgan Healthcare Conference

December 28, 2021

Adaptive Biotechnologies Announces New Data Demonstrating the Benefit of Serial MRD Testing with the clonoSEQ® Assay in Patients with Blood Cancers at the 63rd ASH Annual Meeting

December 12, 2021

Adaptive Biotechnologies and Collaborators to Present More than 30 Abstracts on Utility of clonoSEQ® in MRD Testing in Blood Cancer Patients at the 63rd ASH Annual Meeting

December 1, 2021

Adaptive Biotechnologies Receives Updated Medicare Coverage for its Minimal Residual Disease (MRD) Assay, clonoSEQ® for Blood Cancer Patients

November 10, 2021

Adaptive Biotechnologies Reports Third Quarter 2021 Financial Results

November 2, 2021

Adaptive Biotechnologies to Report Third Quarter Financial Results on November 3, 2021

October 5, 2021

Adaptive Biotechnologies Presents New Data During IDWeek Demonstrating the Capability of Its Immune Medicine Platform to Distinguish Between SARS-CoV-2 Infection and Vaccine Response and Detect Lyme Disease

October 1, 2021

Adaptive Biotechnologies Launches Enhanced clonoSEQ® Assay Reports for Patients with Chronic Lymphocytic Leukemia, Now Featuring IGHV Mutation Status

September 29, 2021

Adaptive Biotechnologies Announces Grand Opening of State-of-the-Art Headquarters and Expands Footprint in Seattle

September 20, 2021

Adaptive Biotechnologies to Present New SARS-CoV-2 Data from its Immune Medicine Platform During IDWeek 2021

September 15, 2021

Adaptive Biotechnologies to Present at the Morgan Stanley Global Healthcare Conference

September 6, 2021

Adaptive Biotechnologies Reports Second Quarter 2021 Financial Results

August 3, 2021

Adaptive Biotechnologies Appoints Nitin Sood as Chief Commercial Officer

August 3, 2021

Adaptive Biotechnologies to Report Second Quarter Financial Results on August 4, 2021

July 11, 2021

New Study Published in Nature Provides Further Evidence that COVID-19 Vaccine Induced T-Cell Response Targets Known SARS-CoV-2 Variants of Concern

June 8, 2021

Adaptive Biotechnologies Included in More than 20 Abstracts at ASCO and EHA 2021 Highlighting Expanding Use Cases for MRD Testing with the clonoSEQ® Assay in Blood Cancer Patients

June 2, 2021

Adaptive Biotechnologies to Participate in Upcoming June 2021 Investor Conferences

May 19, 2021

Adaptive Biotechnologies Reports First Quarter 2021 Financial Results

May 4, 2021

Adaptive Biotechnologies to Present at the BofA Securities 2021 Virtual Healthcare Conference

April 26, 2021

Adaptive Biotechnologies to Report First Quarter Financial Results on May 5, 2021

April 11, 2021

Adaptive Biotechnologies Strengthens Expertise and Diversity of Board of Directors with Appointments of Leslie Trigg and Katey Owen

March 16, 2021

Adaptive Biotechnologies Announces FDA Emergency Use Authorization for T-Detect™ COVID to Confirm Recent or Prior COVID-19 Infection

March 4, 2021

Adaptive Biotechnologies to Present at the Cowen 41st Annual Healthcare Conference

February 24, 2021

Adaptive Biotechnologies Reports Fourth Quarter and Full Year 2020 Financial Results

February 23, 2021

Adaptive Biotechnologies Launches T-Detect™ COVID, First Clinical T-Cell Based Test for Patients to Confirm Recent or Prior COVID-19 Infection

February 22, 2021

Adaptive Biotechnologies Expands Collaboration with Labcorp to Increase Access to Growing Research and Clinical Diagnostic Portfolio

February 22, 2021

Adaptive Biotechnologies to Report Fourth Quarter and Full Year 2020 Financial Results on February 24, 2021

February 1, 2021

Adaptive Biotechnologies to Collaborate with AstraZeneca in Mapping the Immune Response to Cancer Antigens to Potentially Inform the Development of Novel Diagnostics and Therapeutics

January 10, 2021

Adaptive Biotechnologies to Present at the 39th Annual J.P. Morgan Healthcare Conference

December 29, 2020

Adaptive Biotechnologies Announces New Clinical Data Demonstrating Impact of clonoSEQ® Assay on Patients with Blood Cancers at the 62nd ASH Annual Meeting

December 5, 2020

Adaptive Biotechnologies and Collaborators to Present Data from More Than 35 Abstracts at ASH 2020 Highlighting Clinical Relevance of MRD Testing with the clonoSEQ® Assay in Blood Cancer Patients

November 22, 2020

Preliminary Data from Real-World Study Demonstrate T-cell Testing Outperforms Antibody Testing in Identifying Past SARS-CoV-2 Infections

November 12, 2020

Adaptive Biotechnologies Reports Third Quarter 2020 Financial Results

November 9, 2020

Adaptive Biotechnologies Announces Collaboration with GSK to Measure Minimal Residual Disease with clonoSEQ® Assay Across its Hematology and Oncology Portfolio

November 9, 2020

Adaptive Biotechnologies to Report Third Quarter Financial Results on November 10, 2020

October 12, 2020

← Newer news releases · Older news releases →

Calls

The 5 newest of 27 calls. Every call is listed under its year.

Decks

The 5 newest of 32 decks. Every deck is listed under its year.